ストックスクリーナーアプリを入手
4.39
1.35%
-0.06
アフターアワーズ：
4.37
-0.02
-0.46%
前日終値:
$4.45
開ける：
$4.582
24時間の取引高:
31,615
Relative Volume:
0.24
時価総額：
$43.68M
収益：
$20.34M
当期純損益:
$-24.52M
株価収益率:
-1.2276
EPS:
-3.5761
ネットキャッシュフロー:
$-5.92M
1週間 パフォーマンス:
-1.57%
1か月 パフォーマンス:
-15.41%
6か月 パフォーマンス:
-37.70%
1年 パフォーマンス:
-49.19%
1日の値動き範囲:
$4.3662
$4.582
1週間の範囲:
$4.27
$5.00
52週間の値動き範囲:
$3.53
$9.12
Scynexis Inc Stock (SCYX) Company Profile
Compare SCYX vs TAK, TEVA, HLN, ZTS, VTRS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SCYX
Scynexis Inc
|
4.39 | 43.68M | 20.34M | -24.52M | -5.92M | -3.5761 |
TAK
Takeda Pharmaceutical Co Adr
|
18.86 | 60.23B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.19 | 45.71B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.26 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
71.05 | 29.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
VTRS
Viatris Inc
|
17.83 | 20.48B | 14.57B | -296.50M | 1.64B | -0.259 |
Scynexis Inc Stock (SCYX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-01-22 | 開始されました | Guggenheim | Buy |
| 2021-01-06 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-07-11 | アップグレード | Needham | Hold → Buy |
| 2018-06-27 | 開始されました | Maxim Group | Buy |
| 2017-10-24 | 開始されました | Guggenheim | Buy |
| 2017-07-10 | 開始されました | ROTH Capital | Buy |
| 2017-05-09 | ダウングレード | Needham | Buy → Hold |
| 2017-03-03 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2016-10-20 | 開始されました | H.C. Wainwright | Buy |
| 2016-10-07 | アップグレード | WBB Securities | Buy → Strong Buy |
| 2016-10-03 | 再開されました | Brean Capital | Buy |
| 2016-08-17 | 開始されました | Guggenheim | Buy |
| 2016-08-09 | 繰り返されました | Needham | Buy |
| 2016-08-09 | アップグレード | WBB Securities | Speculative Buy → Buy |
| 2016-03-28 | 開始されました | Brean Capital | Buy |
| 2015-12-29 | 開始されました | WBB Securities | Speculative Buy |
| 2015-11-16 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2015-06-10 | 開始されました | Needham | Buy |
| 2014-05-29 | 開始されました | Canaccord Genuity | Buy |
| 2014-05-29 | 開始されました | RBC Capital Mkts | Outperform |
すべてを表示
Scynexis Inc (SCYX) 最新ニュース
SCYNEXIS, Inc. (SCYX) Stock Price, News, Quote & History - Yahoo! Finance Canada
SCYNEXIS, Inc. Announces Appointment of Steven K. Burke, M.D. to its Board of Directors, Effective September 18, 2026 - marketscreener.com
SCYNEXIS Appoints Nephrology Veteran Steven K. Burke to Board of Directors - Minichart
SCYNEXIS adds veteran biopharma leader to board - TipRanks
Scynexis appoints Steven Burke to board of directors - Investing.com
Scynexis (NASDAQ: SCYX) adds kidney drug specialist to its board - Stock Titan
SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors - The Manila Times
SCYNEXIS, Inc. (SCYX) Stock Price Prediction for 2026, 2030-2040 - Traders Union
Scynexis appoints Todd Minga as senior VP of R&D By Investing.com - Investing.com Australia
Scynexis appoints Todd Minga as senior VP of R&D - Investing.com
SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development - The Manila Times
A kidney specialist joins SCYNEXIS to lead rare-disease research - Stock Titan
SCYNEXIS Inc Extraordinary Shareholders Meeting Transcript - GuruFocus
SCYNEXIS at Cantor healthcare conference: rare-disease push takes shape By Investing.com - Investing.com South Africa
Scynexis (SCYX) awards CFO 100,000 stock options vesting over 4 years - Stock Titan
New Scynexis (SCYX) CFO reports no company shares - Stock Titan
SCYNEXIS INC (NASDAQ: SCYX) Appoints Sanjay Subramanian as CFO with $500,000 Annual Salary - Kalkine Media
SCYX: Phase II trial of SCY-770 for ADPKD to launch by year-end, targeting major unmet need - TradingView
SCYNEXIS at Cantor healthcare conference: rare-disease push takes shape - Investing.com
Scynexis names Sanjay Subramanian as chief financial officer - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Form 8K Scynexis Inc For: 10 September By Investing.com - Investing.com Nigeria
SCYNEXIS, Inc. Announces Executive Changes, Effective September 9, 2026 - marketscreener.com
SCYX Looks 72.0% Undervalued on GF Value™ but Remains a Possible Value Trap - GuruFocus
SCYNEXIS, Inc. Announces CFO Changes, Effective September 9, 2026 - marketscreener.com
SCYNEXIS Appoints Sanjay Subramanian CFO as Biotech Advances Rare Disease Pipeline - citybiz
SCYNEXIS Names Sanjay Subramanian as CFO - marketscreener.com
Scynexis names Sanjay Subramanian as chief financial officer By Investing.com - Investing.com India
SCYNEXIS appoints new CFO amid leadership transition - TipRanks
Scynexis Announces Appointment Of Sanjay Subramanian As Chief Financial Officer - TradingView
SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer - marketscreener.com
A new finance chief brings 20 years of experience to SCYNEXIS - Stock Titan
Scynexis Appoints New CFO Amid Transition - Intellectia AI
Scynexis Inc (SCYX) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
SCYNEXIS Inc. (SCYX) Advances 1.92% to $5.32 as Stock Holds Above Key $5.05 SupportDiamond Pattern - vinanet.vn
Scynexis Inc (SCYX) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
SCYNEXIS, Inc. (SCYX) latest stock news and headlines - Yahoo Finance Australia
SCYNEXIS to Participate in Upcoming Investor Conferences - The Manila Times
SCYX Q2 2026 Earnings: EPS Soars to $0.63, Crushing Consensus by 221.9%Earnings Season Preview - dars.gov.et
SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - manilatimes.net
Press Release: SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - Moomoo
SCYNEXIS (SCYX) Market: Moves 3.60% Up to $5.33; Boundary Watch: the Near-Term Reference Band Stretches From $5.06 to $5.60 under the Current SnapshotShort Setup Alerts - vinanet.vn
SCYNEXIS (NASDAQ:SCYX) Upgraded at Wall Street Zen - MarketBeat
SCYX Q1 2026 Earnings: Deep EPS Miss and Missing Revenue Put Pipeline Execution in FocusEstimate Dispersion - vinanet.vn
SCYNEXIS (SCYX) investors CVI and Heights disclose 5.9% ownership stake - Stock Titan
Revenue per share of SCYNEXIS, Inc. – DUS:135 - TradingView
Free cash flow per share of SCYNEXIS, Inc. – DUS:135 - TradingView
SCYNEXIS, Inc. Earnings and Revenue – DUS:135 - TradingView
135 Forecast — Price Target — Prediction for 2027 - TradingView
SCYNEXIS, Inc.: Fundamental Analysis and Financial Ratings | 135 | US8112923094 - marketscreener.com
Great Point Partners (SCYX) reports 9.99% beneficial stake in Scynexis - Stock Titan
Scynexis Inc (SCYX) 財務データ
収益
当期純利益
現金流量
EPS
0.18%
0.69%
大文字化:
|
ボリューム (24 時間):